Breast Cancer Clinical Trial
Study of Zoledronic Acid Administered Monthly Versus Every 3 Months in Multiple Myeloma and Breast Cancer Patients Who Were Treated With Zoledronic Acid the Prior Year
Summary
The primary objective of this study is to investigate the repeat-dose pharmacokinetic (PK) profile of zoledronic acid when administered every 4 weeks versus every 12 weeks, in patients treated with 9-20 infusions of zoledronic acid during the previous 10-15 months.
Eligibility Criteria
Inclusion Criteria:
Male or female between 18-75 years of age
Multiple myeloma or breast cancer with bone involvement
Treatment with zoledronic acid for bone lesions between 10-15 months prior to entry into study with a total of 9-20 infusions received.
Exclusion Criteria:
Current active dental problems or recent (within 8 weeks) or planned dental or jaw surgery
Active or uncontrolled infection, liver, or renal disease
History of treatment with intravenous bisphosphonates
Diagnosis of metabolic bone disorders other than osteoporosis (e.g. Paget's disease)
Other protocol-defined inclusion/exclusion criteria may apply.
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 6 Locations for this study
West Hollywood California, 90069, United States
Greenwood Village Colorado, , United States
Norwalk Connecticut, 06856, United States
Pittsburgh Pennsylvania, 15232, United States
Salt Lake City Utah, 84112, United States
Burlington Vermont, 05404, United States
Richmond Virginia, 23230, United States
How clear is this clinincal trial information?